Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation~* Participant meets Adult Treatment Panel (ATP) III High Risk criteria~Exclusion Criteria:~* Females who are pregnant or breastfeeding~* Participant consumes more than 14 alcoholic beverages per week~* Participant has been treated with an investigational drug within the last 30 days~* Participant has congestive heart failure (New York Heart Association \[NYHA\] Type III or IV)~* Participant has had gastric bypass~* Participant is newly diagnosed with type 1 or 2 diabetes~* Participant is Human Immunodeficiency Virus (HIV) positive~* Participant has a history of drug or alcohol abuse within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ezetimibe/simvastatin 10/40 (Type: EXPERIMENTAL): Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
- atorvastatin 40 mg (Type: ACTIVE_COMPARATOR): Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).